EUVIMEDEUVIMED entdecken
Crossref

Relationship between Anaplastic Lymphoma Kinase Inhibitors and Epileptic Seizure Disorder: A Post-Marketing Surveillance Study

Yoshihiro Noguchi, Hiroki Asano, Rikuto Masuda, Yuta Teshigawara, Makiko Go, Michio Kimura, Eiseki Usami, Tomoaki Yoshimura

Oncology · 2024

DOI: 10.1159/000539426 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Yoshihiro Noguchi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Lactams, Carbazoles, Piperidines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Anaplastic lymphoma kinase (ALK) has been to be involved in the uptake and regulation of dopamine 2 receptor (D2R), a G protein-coupled receptor expressed in various brain regions. Therefore, it is crucial to understand the relationship between ALK inhibitors and seizures is an important issue. This study investigated the relationship between ALK inhibitors and seizures.

Methods

This study investigated the relationship between ALK inhibitors and seizures through a disproportionality analysis using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). The target drugs were the ALK inhibitors crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib. The seizures covered were defined high-level group term (HLGT): “Seizures (incl. subtype)” including high-level term (HLT): “seizures and seizure disorders NEC.” This study used the information component (IC), a signal score, as a Bayesian statistical method for disproportionality analysis. The signal detection criteria used in this study were the same as those reported previously: a lower limit of 95% credible interval (CrI) for IC >0.

Results

The signal scores of '“seizures and seizure disorders not elsewhere classified (NEC)” “for each ALK inhibitor were crizotinib (IC: −0.00052, 95% CrI: −0.38–0.27), ceritinib (IC: 1.18, 95% CrI: 0.68–1.54), alectinib (IC: 0.68, 95% CrI: 0.19–1.02), brigatinib (IC: 1.04, 95% CrI: 0.32–1.54), and lorlatinib (IC: 0.82, 95% CrI: 0.11–1.32). On the other hand, “generalized tonic-clonic seizures,” “partial simple seizures NEC,” “absence seizures,” and “partial complex seizures” had no or few reported cases, and no signal was detected.

Conclusion

To our knowledge, this is the first report to evaluate the relationship between ALK inhibitors and seizures using post-marketing surveillance data. These results suggest that ceritinib, alectinib, brigatinib, and lorlatinib, which are highly brain-migrating drugs, are associated with seizures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anaplastic Lymphoma KinaseLactamsCarbazolesPiperidinesPyrimidinesProtein Kinase InhibitorsPyrazolesCrizotinibProduct Surveillance, PostmarketingSulfonesOrganophosphorus CompoundsHumansAminopyridinesLactams, MacrocyclicUnited StatesMaleFemaleMiddle AgedUnited States Food and Drug AdministrationAdultAdverse Drug Reaction Reporting SystemsEpilepsyBayes TheoremAgedSeizures

Stichwörter der Autor:innen

Anaplastic lymphoma kinase inhibitorsDisproportionality analysisEpileptic seizure disorderFDA Adverse Event Reporting System

Substanzen

Anaplastic Lymphoma KinasealectinibLactamsCarbazolesPiperidinesPyrimidinesProtein Kinase InhibitorsceritinibPyrazolesCrizotinib

Autor:innen und Institutionen

  • Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
  • Laboratory of Medical Collaborative Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
  • Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan.

Zitieren

APA

Noguchi, Y., Asano, H., Masuda, R., Teshigawara, Y., Go, M., Kimura, M., Usami, E., & Yoshimura, T. (2024). Relationship between Anaplastic Lymphoma Kinase Inhibitors and Epileptic Seizure Disorder: A Post-Marketing Surveillance Study. Oncology. https://doi.org/10.1159/000539426

Vancouver

Noguchi Y, Asano H, Masuda R, Teshigawara Y, Go M, Kimura M, et al. Relationship between Anaplastic Lymphoma Kinase Inhibitors and Epileptic Seizure Disorder: A Post-Marketing Surveillance Study. Oncology. 2024. doi:10.1159/000539426

BibTeX
@article{Noguchi2024,
  author = {Noguchi, Yoshihiro and Asano, Hiroki and Masuda, Rikuto and Teshigawara, Yuta and Go, Makiko and Kimura, Michio and Usami, Eiseki and Yoshimura, Tomoaki},
  title = {Relationship between Anaplastic Lymphoma Kinase Inhibitors and Epileptic Seizure Disorder: A Post-Marketing Surveillance Study},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000539426}
}
Kostenlos starten →